Abstract
MYL-1402O (Abevmy®, Lextemy®) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy® is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid cancers. Lextemy® is approved for all indications as reference bevacizumab, except in recurrent ovarian cancer. MYL-1402O has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab, and the pharmacokinetic similarity of the agents has been shown in healthy male subjects. MYL-1402O demonstrated clinical efficacy equivalent to that of reference bevacizumab in patients with non-squamous NSCLC. The tolerability, safety and immunogenicity profiles of MYL-1402O were consistent with those of reference bevacizumab. The role of reference bevacizumab in the management of solid cancers is well established and MYL-1402O provides an effective biosimilar alternative for patients requiring bevacizumab therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Digital Features for this Adis Biosimilar Brief can be found at https://doi.org/10.6084/m9.figshare.17074784. |
Biosimilar to reference bevacizumab. |
Equivalent efficacy and tolerability to reference bevacizumab in patients with stage IV non-squamous NSCLC. |
Similar pharmacokinetic and pharmacodynamic properties to those of reference bevacizumab. |
MYL-1402O (as Abevmy®) is approved for all indications for which reference bevacizumab is approved. |
1 Introduction
MYL-1402O (Abevmy®, Lextemy®) is a biosimilar of the reference monoclonal anti-vascular endothelial growth factor antibody bevacizumab. Abevmy® is approved for the same indications as the reference drug in the EU (Table 1) [1]. Lextemy is approved for the same indications as bevacizumab, apart from recurrent ovarian cancer [2]. The pharmacokinetic similarity of MYL-1402O to EU- and US-sourced reference bevacizumab has been demonstrated [3]. This article summarizes, from an EU perspective, the key features of MYL-1402O and its clinical use in the treatment of solid cancers, focusing on non-squamous non-small cell lung cancer (NSCLC).
2 Clinical Pharmacology
Pharmacokinetic equivalence of MYL-1402O to EU- and US-sourced bevacizumab was demonstrated in a pharmacokinetic study in healthy male subjects (Table 2). A parallel study design was selected as the half-life of bevacizumab is approximately 20 days. Although a subtherapeutic dose (1 mg/kg) of bevacizumab was administered to limit exposure in healthy subjects, this dose was within the range where the pharmacokinetics of bevacizumab are expected to be linear [3].
MYL-1402O demonstrated pharmacodynamic equivalence and similarity in physicochemical properties to EU-sourced bevacizumab in pre-clinical studies (Table 2). Differences in post-translational modifications were detected in MYL-1402O (Table 2), which have the potential to affect the efficacy of biological products via changes in antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). However, as bevacizumab does not exhibit ADCC nor CDC, these differences in post-translational modifications are unlikely to be clinically relevant [4].
3 Clinical Efficacy
The efficacy of MYL-1402O and reference bevacizumab was investigated in a multicentre, randomised, double-blind phase III equivalence trial in 671 patients with stage IV non-squamous NSCLC (Table 2, Fig. 1). Patients aged ≥ 18 years were treated intravenously with MYL-1402O or reference bevacizumab 15 mg/kg in 3-week cycles for 18 weeks, in addition to carboplatin to a target area under the concentration-time curve of 6 mg/mL·min and paclitaxel 175 or 200 mg/m2. Treatment was continued until disease progression or unacceptable toxicity, whichever occurred earlier. Treatment response was evaluated by independent review using Response Evaluation Criteria in Solid Tumours 1.1 criteria at any time point within the first 18 weeks of treatment. After the initial 18-week combination treatment period, monotherapy with MYL-1402O or reference bevacizumab 15 mg/kg once every 3 weeks was available in eligible patients [i.e. those with stable disease or who had achieved a complete (CR) or partial (PR) response] for a further 24 weeks. Patients who at week 42 had maintained stable disease or who had achieved a CR or PR continued to receive MYL-1402O or reference bevacizumab until disease progression or discontinuation of treatment or termination of study. Baseline characteristics were generally well balanced between treatment arms [5].
Therapeutic equivalence of MYL-1402O to reference bevacizumab was demonstrated at week 18 analysis in the intent-to-treat population (primary efficacy analysis; Fig. 1). Overall response rates were similar between the MYL-1402O and reference bevacizumab treatment arms, and both EMA and FDA requirements for equivalence were met. The 95% confidence intervals of the risk difference were contained within the predefined equivalence margin of ± 12.5% (EMA requirement), and the 90% confidence intervals of the ratio of the overall response rate fell within the predefined equivalence margin of 0.73–1.36 (FDA requirement) [5].
Analyses at week 42 supported the therapeutic equivalence of MYL-1402O to reference bevacizumab [5]. The disease control rate in the MYL-1402O treatment arm was congruent with the rate in the bevacizumab treatment arm (Fig. 1). No significant differences between the MYL-1402O and reference bevacizumab arms were reported in median progression-free survival (7.6 months vs 9.0 months) and overall survival [OS] (70.0% vs 75.4%) rates; median OS was not reached in both treatment arms. The duration of response was consistent between treatment arms (7.7 vs 6.9 months) [5]. Data beyond week 42 indicated the OS in the MYL-1402O and reference bevacizumab arms was 71.9 and 77.3 weeks [4].
4 Tolerability and Safety
The safety and tolerability profile of MYL-1402O was similar to reference bevacizumab during a phase III trial in patients with stage IV non-squamous NSCLC. In total, 664 patients were analysed in the safety set, including 335 patients in the MYL-1402O treatment arm. In the MYL-1402O and reference bevacizumab treatment arms, treatment-related adverse events (TRAEs) were reported in 35.8% vs 35.0% of patients, serious TRAEs were reported in 5.1% vs 6.7% of patients, TRAEs leading to treatment discontinuation in 3.9% vs 4.0% of patients and TRAEs leading to death in 2.1% and 1.2% of patients. The most commonly reported TRAEs with an incidence ≥ 5% of patients were anaemia (6.6% vs 6.7%), thrombocytopenia (6.3% vs 5.5%) and diarrhoea (6.0% vs 3.6%) [4].
The incidence of adverse events of special interest (AESI) were generally similar between the MYL-1402O and reference bevacizumab treatment arms. The incidence of any-grade AESI at week 18 (i.e. when patients received combination therapy with MYL-1402O or reference bevacizumab and chemotherapy) in the MYL-1402O and reference bevacizumab treatment arms was 16.1% vs 20.1%; hypertension (3.6% vs 3.3%) and epistaxis (1.5% vs 5.2%) were the only AESI with an incidence ≥ 3% in any treatment arm. Grade ≥ 3 AESI were reported in 6.9% vs 7.0% of patients. At week 42 (i.e. when patients received monotherapy with MYL-1402O or reference bevacizumab), the incidence of any-grade (10.5% vs 8.0%) and grade ≥ 3 AESI (2.0% vs 2.5%) were consistent between treatment arms [4].
5 Immunogenicity
The immunogenicity of MYL-1402O was comparable to reference bevacizumab (Table 2). During a phase III trial in patients with stage IV non-squamous NSCLC, the incidence of treatment-emergent anti-drug antibodies (ADAs) was similar between the MYL-1402O and reference bevacizumab treatment arms (Table 2) [5]. In healthy male subjects, the majority (≥ 89%) of patients in the MYL-1402O, EU- and US-sourced reference bevacizumab treatment arms tested positive for ADAs on day 15. A similar decrease in ADA-positive subjects over time was observed across the trial arms [3]. Furthermore, in an analysis of the total trial population, higher levels of ADAs did not appear to have clinically significant effects on the pharmacokinetics of bevacizumab in healthy male subjects (Table 2) [3].
6 Conclusion
MYL-1402O is a bevacizumab biosimilar with similar physicochemical and functional properties to the reference product (Table 2). Based on the efficacy, tolerability and safety characteristics in clinical data available from patients with non-squamous NSCLC (Table 2), MYL-1402O (as Abevmy®) has been approved in the EU for all indications for which reference bevacizumab is approved (Table 1).
Change history
18 April 2022
A Correction to this paper has been published: https://doi.org/10.1007/s11523-022-00882-1
References
European Medicines Agency. Abevmy (bevacizumab): EU summary of product characteristics. 2021. https://www.ema.europa.eu/. Accessed 24 Nov 2021.
European Medicines Agency. Lextemy (bevacizumab): EU summary of product characteristics. 2021. https://www.ema.europa.eu/. Accessed 24 Nov 2021.
Hummel M, Bosje T, Shaw A, et al. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. J Cancer Res Clin Oncol. 2021. https://doi.org/10.1007/s00432-021-03628-0.
European Medicines Agency. Abevmy (bevacizumab): EU public assessment report. 2021. https://www.ema.europa.eu/. Accessed 24 Nov 2021.
Socinski MA, Waller CF, Idris T, et al. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. Ther Adv Med Oncol. 2021. https://doi.org/10.1177/17588359211045845.
Acknowledgements
During the peer review process the manufacturer of MYL-1402O was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
Arnold Lee is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
The manuscript was reviewed by: K. Araki, Department of Medical Oncology, Gunma Prefectural Cancer Center, Ota, Japan; P. Gascon, Department of Hematology-Oncology, University of Barcelona, Barcelona, Spain
The original version of this article was revised due to a retrospective Open Access order.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lee, A. MYL-1402O: A Bevacizumab Biosimilar. Targ Oncol 17, 85–88 (2022). https://doi.org/10.1007/s11523-021-00858-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-021-00858-7